(Q34714444)

4 August 2017

1 reference

title

Disparity between angiographic regression and clinical event rates with hydrophobic statins (English)

1 reference

4 August 2017

1 reference

1 reference

Kazuo Ichihara

1

1 reference

4 August 2017

Kumi Satoh

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

359

1 reference

4 August 2017

issue

9324

1 reference

4 August 2017

page(s)

2195-2198

1 reference

Regulation of the mevalonate pathway

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

In vitro and in vivo synthesis of dolichol and other main mevalonate products in various organs of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Possible involvement of 3-hydroxymethylglutaryl-CoA reductase in determining the side-chain length of ubiquinone in rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

4-Hydroxybenzoate:Polyprenyl transferase and the prenylation of 4-aminobenzoate in mammalian tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909098-0

7 January 2021

10.1016/S0140-6736(02)09098-0

Identifiers

DOI

1 reference

4 August 2017

1 reference